Showing 1,501 - 1,520 results of 23,444 for search '"world"', query time: 0.10s Refine Results
  1. 1501
  2. 1502
  3. 1503
  4. 1504
  5. 1505
  6. 1506
  7. 1507
  8. 1508

    AI for IMPACTS Framework for Evaluating the Long-Term Real-World Impacts of AI-Powered Clinician Tools: Systematic Review and Narrative Synthesis by Christine Jacob, Noé Brasier, Emanuele Laurenzi, Sabina Heuss, Stavroula-Georgia Mougiakakou, Arzu Cöltekin, Marc K Peter

    Published 2025-02-01
    “…It integrates clinical context and real-world implementation factors, offering a more comprehensive approach to evaluating AI tools. …”
    Get full text
    Article
  9. 1509
  10. 1510
  11. 1511

    Dynamic Competition and Cooperation of Road Infrastructure Investment of Multiple Tourism Destinations: A Case Study of Xidi and Hongcun World Cultural Heritage by Jun Li, Wenna Zhang, Honggang Xu, Jie Jiang

    Published 2015-01-01
    “…The system dynamics method is used to model dynamic interactions among destinations and to simulate the dynamic evolution of the competition on the tourism market. A case study of the World Cultural Heritage Sites, Xidi and Hongcun villages, shows the competition for road infrastructure investment can produce a win-win situation and bring the cooperation on investment due to the positive externality of transport infrastructure and two villages show a tendency to merge into one bigger destination. …”
    Get full text
    Article
  12. 1512

    Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study by Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova, Alexey Kalpinskiy, Sufia Safina, Andrei Lebedinets, Vladislav Petkau, Elvira Parsadanova, Maria Turganova, Aleksei Shkurat, Natalia Tovbik, Elena Tkacheva, Yulia Anzhiganova, Olga Novikova, Varvara Bragina, Ruslan Zukov, Rashida Orlova

    Published 2024-12-01
    “…Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). …”
    Get full text
    Article
  13. 1513

    Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study by Nayana Hitesh Patel, Niket H. Patel, Molina Niket Patel, Harsha K. Bhadarka, Kairavi Sunilkumar Vyas

    Published 2023-04-01
    “…Background: Biosimilar drugs have broadened the treatment options in assisted reproductive technology (ART). Real-world data comparing clinical outcomes of originator follitropin alfa (Gonal-f®) with its biosimilars are required to enrich the body of evidence for clinical decision-making on choice of drug. …”
    Get full text
    Article
  14. 1514
  15. 1515

    Frequency and types of antibiotic usage in a referral neonatal intensive care unit, based on the world health organization classification (AwaRe) by Farzaneh Hematian, Seyyed Mohammad Hassan Aletayeb, Masoud Dehdashtian, Mohammad Reza Aramesh, Arash Malakian, Mahboobeh Sadat Aletayeb

    Published 2025-01-01
    “…This study aimed to evaluate the dose and duration of antibiotic therapy and identify the prescribing pattern of antibiotics based on the Access, Watch, and Reserve (AWaRe) classification recommended by the World Health Organization (WHO). Results Out of 502 examined patient files, antibiotics were prescribed for 483 neonates. …”
    Get full text
    Article
  16. 1516
  17. 1517

    Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea by Michael Berhe Solomon, Ghirmay Ghebrekidan Ghebremeskel, Oliver Okoth Achila, Aron Rezene Mebrahtu, Mohammed Elfatih Hamida, Araia Berhane Mesfin

    Published 2025-01-01
    “…Abstract Real-world data on treatment outcomes or the quality of large-scale chronic hepatitis B (CHB) treatment programs in sub-Saharan Africa (SSA) is extremely difficult to obtain. …”
    Get full text
    Article
  18. 1518
  19. 1519

    Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis by David P Carbone, David Spigel, Jeffrey S Ross, Karthikeyan Murugesan, Gerald Li, Richard S P Huang, Ryon P Graf, Geoffrey R Oxnard, Alexa Schrock, Liangliang Zhang, Khaled Tolba, Jacob Sands

    Published 2023-01-01
    “…Comparing low TMB (<10 muts/Mb), high TMB (10–19 muts/Mb), and very high TMB (≥20 muts/Mb) receiving ICPI alone, we observed a stepwise increase in median rwPFS (real world-progression free survival) (6.5, 7.5, 17.2 months) and rwOS (real world-overall survival) (10.1, 11.8, 26.9 months) as TMB increased. …”
    Get full text
    Article
  20. 1520